ACAD vs PATH · P/E 15, rev $957.8M vs P/E 19, rev $1.61B
ACADIA Pharmaceuticals Inc (ACAD) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ACAD and PATH stock pages for the full models.
Not investment advice.